Pherecydes Pharma
Created in 2006
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
4,360Activities
Technologies
Entity types
Location
22 Bd Benoni Goullin, 44200 Nantes, France
Nantes
France
Employees
Scale: 11-50
Estimated: 9
SIREN
493252266Engaged corporates
13
10 4Added in Motherbase
5 years, 11 months ago
biotech Value proposition
At the forefront of the fight against antibioresistant bacteria
Pherecydes Pharma develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections in humans, particularly those resistant to antibiotics. Phages are natural predators of bacteria and have no demonstrated effect on eukaryotic cells, including human cells.
Antimicrobial resistant bacteria or AMR are responsible for over 700,000 death a year in 2014 according to the WHO. This number might reach over 10,000,000 by 2050 if nothing is done, and no new class of antibiotics has been discovered in the last 30 years.
Phages represent one of the most promising approach to fight these AMR infections.
Pherecydes Pharma has introduced the concept of precision phagotherapy, which consists in treating each patient according to the activity of the phages on the bacterial strain responsible for the infection. Treatments are therefore individualized and adapted to each case.
Pherecydes Pharma has selected as priority bacterial targets Staphylococcus aureus, Pseudomonas aeruguinosa and Escherichia coli, that have been identified by the WHO among the most dangerous infections. These three bacteria alone account for the vast majority of nosocomial infections in industrialized countries, and as much as over 2/3rd of hospital resistant infections in France according to a recent study.
Some of the patented phages developed by Pherecydes Pharma have already been administered as part of compassionate treatments in France under the supervision of French Health authorities (ANSM).
Biotechnology, Microbiology, Bacteriophage, Phage therapy, Phage, Antibiotic resistance, Bacterial infections, Respiratory tract infections, Bone and joint infections, Burn wound skin infections, Infectious Disease, Antibacterial treatments, Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coliOriginal language
At the forefront of the fight against antibioresistant bacteria
Pherecydes Pharma develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections in humans, particularly those resistant to antibiotics. Phages are natural predators of bacteria and have no demonstrated effect on eukaryotic cells, including human cells.
Antimicrobial resistant bacteria or AMR are responsible for over 700,000 death a year in 2014 according to the WHO. This number might reach over 10,000,000 by 2050 if nothing is done, and no new class of antibiotics has been discovered in the last 30 years.
Phages represent one of the most promising approach to fight these AMR infections.
Pherecydes Pharma has introduced the concept of precision phagotherapy, which consists in treating each patient according to the activity of the phages on the bacterial strain responsible for the infection. Treatments are therefore individualized and adapted to each case.
Pherecydes Pharma has selected as priority bacterial targets Staphylococcus aureus, Pseudomonas aeruguinosa and Escherichia coli, that have been identified by the WHO among the most dangerous infections. These three bacteria alone account for the vast majority of nosocomial infections in industrialized countries, and as much as over 2/3rd of hospital resistant infections in France according to a recent study.
Some of the patented phages developed by Pherecydes Pharma have already been administered as part of compassionate treatments in France under the supervision of French Health authorities (ANSM).
Default Page
http://www.pherecydes-pharma.com/ - Website is disabled or domain is for sale
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 La French Tech Alpes Government Administration, French Tech | La French Tech Alpes Government Administration, French Tech | Other 31 Mar 2023 | | |
 Alexion Pharmaceuticals, Inc. Pharmaceutical, Biotechnology, Biotechnology Research | Alexion Pharmaceuticals, Inc. Pharmaceutical, Biotechnology, Biotechnology Research | Other 18 Jun 2023 | | |
 Gustave Roussy Health, Hospitals and Health Care | Gustave Roussy Health, Hospitals and Health Care | Other 18 Jun 2023 | | |
 La French Tech Grand Paris French Tech, IT Services and IT Consulting | La French Tech Grand Paris French Tech, IT Services and IT Consulting | Other 27 Mar 2023 | | |
 La French Tech Lille French Tech, IT Services and IT Consulting | La French Tech Lille French Tech, IT Services and IT Consulting | Other 27 Mar 2023 | | |
 La French Tech Nantes French Tech, IT Services and IT Consulting | La French Tech Nantes French Tech, IT Services and IT Consulting | Other 30 Mar 2023 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 27 Mar 2023 | | |
 numeum IT Services and IT Consulting | numeum IT Services and IT Consulting | Other 27 Mar 2023 | | |
 Elaia Startup accelerator & VC, Venture Capital and Private Equity Principals | Elaia Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 27 Mar 2023 | | |
 La French Tech Media, Government Administration | La French Tech Media, Government Administration | Other 18 Jun 2023 | | |